Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TARS
TARS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TARS News
Tarsus Pharmaceuticals Q1 2026 Earnings Call Highlights
4d ago
seekingalpha
Tarsus (TARS) Q1 2026 Earnings Transcript
4d ago
NASDAQ.COM
Tarsus Pharmaceuticals Q1 Earnings Announcement Scheduled
5d ago
seekingalpha
Tarsus Pharmaceuticals to Report Q1 2026 Financial Results on May 6
Apr 29 2026
Newsfilter
Tarsus Initiates Clinical Trial for Lyme Disease Prevention
Mar 31 2026
Newsfilter
Tarsus Pharmaceuticals Executive Sells Shares Amid Strong Sales Growth
Mar 24 2026
Fool
Tarsus Pharmaceuticals Executive Sells Shares for Tax Obligations
Mar 24 2026
NASDAQ.COM
TARSUS PHARMACEUTICALS INC - QUALIFIED FOR EXTRA MILESTONES AND GRADUATED ROYALTIES FOR TP-03 IN GREATER CHINA
Mar 23 2026
moomoo
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 24 2026
seekingalpha
Tarsus Pharmaceuticals Reports Narrowed Losses in 2025 Financials
Feb 24 2026
NASDAQ.COM
Tarsus Pharmaceuticals Q4 Earnings Analysis
Feb 23 2026
seekingalpha
Tarsus Pharmaceuticals Appoints New Board Member
Feb 18 2026
Newsfilter
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Nov 19 2025
NASDAQ.COM
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Nov 05 2025
NASDAQ.COM
Tarsus Sets Q4 Sales Goal of $140M–$145M Amidst Increased XDEMVY Adoption and Pipeline Development
Nov 04 2025
SeekingAlpha
HC Wainwright & Co. Reaffirms Buy Rating for Tarsus Pharmaceuticals and Increases Price Target to $88
Oct 20 2025
Benzinga
Show More News
